MapLight Therapeutics makes $372.5m in series D financing
MapLight Therapeutics has announced an oversubscribed $372.5 million Series D financing. The financing was co-led by Forbion and Life Sciences at Goldman Sachs Alternatives, with participation from additional new investors, including Sanofi, accounts advised by T Rowe Price Investment Management, Inc. and Avego BioScience Capital. … Read More